News

A first-of-its-kind study reveals artificial intelligence (AI)-driven insights on hair loss trends, highlighting the impact of genetics, hormones, and COVID-19 on alopecia.

A systematic review reveals significant Treg cell deficiencies in vitiligo, highlighting their role as therapeutic targets for improved treatment strategies.

Explore how genetic factors influence acute and chronic urticaria, revealing potential for personalized treatment strategies.

Aesthetic medicine embraces a holistic approach to skin quality, defining it through measurable categories that enhance personalized treatment strategies.

Discover how trifarotene, a novel retinoid, effectively addresses adult acne and its long-term effects, enhancing skin health and quality of life.

This review of the latest dermatologic studies includes insights into ocular safety during laser procedures, radiation dermatitis prevention and management, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Renata Block, DMSc, MMS, PA-C, interviews Amy Snow, PA-C, who shares how she transformed career roadblocks into a mobile dermatology clinic delivering free care and hope across Oregon.

A recent study reveals distinct patterns of nonsegmental vitiligo lesions on hands.

For pregnant women, formulations with niacinamide, vitamin E, hyaluronic acid, and peptides may help support barrier function and reduce pigmentation without compromising safety.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.

New insights reveal shared and allergen-specific immune responses in allergic contact dermatitis.

At a recent Dermatology Times Case-Based Roundtable event, David Cotter, MD, PhD, reviewed treatment considerations for older patients with moderate to severe PsO who are candidates for biologic therapy.

Haut.AI has launched the SPF Truth Booth and SPF Protection Power List, using AI to promote sun safety and personalized patient insights.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Turn Therapeutics initiates a groundbreaking clinical trial for GX-03, the first topical IL-36 inhibitor targeting moderate to severe eczema.

Both regulatory-approved and pipeline treatments for moderate to severe HS demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

A national Delphi survey reveals critical insights into CHE management in France, highlighting the need for standardized assessment and guidelines.

Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the US, offering a new treatment for adults with severe alopecia areata.

The pharmaceutical companies announced an exclusive global license and transfer agreement for the advancement and commercialization of Spevigo.

Melanoma survivors share their diagnoses and advocate for early detection, routine skin exams, and public education to save lives.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about APG777 EASI-75 response rates in atopic dermatitis, the unblinding of VYN202 after a safety pause, spesolimab and skin clarity between flares, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

OJM Group’s David Mandell, JD, MBA, shares financial planning strategies for physicians facing new tax laws and market volatility.

Ethanol-based hand sanitizer showed no visible skin toxicity in rats, but subclinical dermatitis raised concerns about dermal test guideline adequacy.

After 4 months of treatment with the dual therapy, patients with refractory vitiligo exhibited an overall 55% remission rate.